and do not have access to the treatment locally, This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study)
Conditions
Brief summary
1. Number of Participants with Continued Access to Roche IMP(s)-Based Therapy and/or Comparator Agent(s)
Detailed description
1. The incidence, nature, and severity of selected adverse events as described in IMP-specific appendices
Interventions
DRUGRO7538483
DRUGINAVOLISIB
DRUGABIRATERONE
DRUGIpatasertib
DRUGTecentriq 1 200 mg concentrate for solution for infusion
DRUGAvastin 25 mg/ml concentrate for solution for infusion.
DRUGTiragolumab
DRUGRozlytrek
Sponsors
F. Hoffmann-La Roche AG
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Number of Participants with Continued Access to Roche IMP(s)-Based Therapy and/or Comparator Agent(s) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The incidence, nature, and severity of selected adverse events as described in IMP-specific appendices | — |
Countries
Belgium, France, Greece, Poland
Outcome results
None listed